Long-term Safety and Efficacy of Benralizumab for Eosinophilic Granulomatosis with Polyangiitis Complicated with Severe Neuropathy

Overview

Journal Intern Med

Specialty General Medicine

Date 2022 Sep 28

PMID 36171130

Authors

Yasuhiko Koga

Seishi Yoshimi

Takashi Harada

Satoshi Suzuki

Takayuki Ohtsuka

Kunio Dobashi

Takeshi Hisada

Affiliations

Soon will be listed here.

Abstract

The efficacy of benralizumab, as well as mepolizumab, to granulomatosis with polyangiitis (EGPA) involved with mononeuritis multiplex remains unclear. We experienced a case of EGPA presenting neuropathy with severe asthma. Muscle weakness due to neuropathy involved with gait disturbance was partly ameliorated by intravenous immunoglobulin therapy. Mepolizumab (100 mg/day) did not promote further improvement of neuropathy. However, the administration of benralizumab instead of mepolizumab improved neuropathy quickly and enabled walking alone. The efficacy of benralizumab for EGPA and its complication has been maintained for over four years. Benralizumab may be a possible treatment for EGPA presenting neuropathy with severe asthma.

Citing Articles

Anti-IL5 Monoclonal Antibodies Reduce Asthma Exacerbations and Corticosteroids Dose in Three Eosinophilic Granulomatosis with Polyangiitis Case Reports.

Skouvaklidou E, Kipourou M, Zisopoulos D, Vounotrypidis P, Katsoulis K Mediterr J Rheumatol. 2023; 34(2):238-244.

PMID: 37654647 PMC: 10466358. DOI: 10.31138/mjr.34.2.238.

The role of anti-eosinophilic therapies in eosinophilic granulomatosis with polyangiitis: a systematic review.

Kouverianos I, Angelopoulos A, Daoussis D Rheumatol Int. 2023; 43(7):1245-1252.

PMID: 37085573 PMC: 10185576. DOI: 10.1007/s00296-023-05326-1.

Editorial: Pathophysiological and clinical advances in asthmatic inflammation from the nasopharynx to the peripheral airway in the respiratory tract systems.

Koga Y, Kamide Y, Hisada T, Ishizuka T Front Pharmacol. 2023; 14:1037610.

PMID: 36726579 PMC: 9885187. DOI: 10.3389/fphar.2023.1037610.

References

Padoan R, Bianchi F, Marchi M, Cazzador D, Felicetti M, Emanuelli E . Benralizumab as a glucocorticoid-sparing treatment option for severe asthma in eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract. 2020; 8(9):3225-3227.e2. DOI: 10.1016/j.jaip.2020.05.033. View

Guntur V, Manka L, Denson J, Dunn R, Dollin Y, Gill M . Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis. J Allergy Clin Immunol Pract. 2020; 9(3):1186-1193.e1. DOI: 10.1016/j.jaip.2020.09.054. View

Levy Y, Uziel Y, Zandman G, Amital H, Sherer Y, Langevitz P . Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis. Ann Rheum Dis. 2003; 62(12):1221-3. PMC: 1754385. DOI: 10.1136/ard.2002.003996. View

Yost B, Gleich G, Jacoby D, Fryer A . The changing role of eosinophils in long-term hyperreactivity following a single ozone exposure. Am J Physiol Lung Cell Mol Physiol. 2005; 289(4):L627-35. DOI: 10.1152/ajplung.00377.2004. View

Ueki Y, Oshikata C, Asai Y, Kaneko T, Hattori N, Tsurikisawa N . [EVALUATION OF A MOTOR AND SENSORY DISTURBANCE QUESTIONNAIRE FOR PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS]. Arerugi. 2019; 68(7):857-868. DOI: 10.15036/arerugi.68.857. View

Sinico R, Di Toma L, Maggiore U, Bottero P, Radice A, Tosoni C . Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005; 52(9):2926-35. DOI: 10.1002/art.21250. View

Tsurikisawa N, Taniguchi M, Saito H, Himeno H, Ishibashi A, Suzuki S . Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol. 2004; 92(1):80-7. DOI: 10.1016/S1081-1206(10)61714-0. View

Miyata Y, Inoue H, Homma T, Tanaka A, Sagara H . Efficacy of Benralizumab and Clinical Course of IgG4 in Eosinophilic Granulomatosis With Polyangiitis. J Investig Allergol Clin Immunol. 2020; 31(4):346-348. DOI: 10.18176/jiaci.0648. View

Nanzer A, Dhariwal J, Kavanagh J, Hearn A, Fernandes M, Thomson L . Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis. ERJ Open Res. 2020; 6(4). PMC: 7682702. DOI: 10.1183/23120541.00451-2020. View

10.

Menzella F, Galeone C, Ghidoni G, Ruggiero P, Capobelli S, Simonazzi A . Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab. Multidiscip Respir Med. 2021; 16(1):779. PMC: 8239622. DOI: 10.4081/mrm.2021.779. View

11.

Furuta S, Iwamoto T, Nakajima H . Update on eosinophilic granulomatosis with polyangiitis. Allergol Int. 2019; 68(4):430-436. DOI: 10.1016/j.alit.2019.06.004. View

12.

Oka N, Kawasaki T, Matsui M, Shigematsu K, Unuma T, Sugiyama H . Two subtypes of Churg-Strauss syndrome with neuropathy: the roles of eosinophils and ANCA. Mod Rheumatol. 2010; 21(3):290-5. DOI: 10.1007/s10165-010-0400-9. View

13.

Lee Y, Hojjati M . Benralizumab as a Potential Adjunctive Therapy in Eosinophilic Granulomatosis With Polyangiitis. J Clin Rheumatol. 2020; 27(8S):S401-S402. DOI: 10.1097/RHU.0000000000001419. View

14.

Evans C, Jacoby D, Fryer A . Effects of dexamethasone on antigen-induced airway eosinophilia and M(2) receptor dysfunction. Am J Respir Crit Care Med. 2001; 163(6):1484-92. DOI: 10.1164/ajrccm.163.6.2007047. View

15.

Koga Y, Aoki-Saito H, Kamide Y, Sato M, Tsurumaki H, Yatomi M . Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis. Front Pharmacol. 2022; 13:865318. PMC: 8960447. DOI: 10.3389/fphar.2022.865318. View

16.

Drake M, Scott G, Blum E, Lebold K, Nie Z, Lee J . Eosinophils increase airway sensory nerve density in mice and in human asthma. Sci Transl Med. 2018; 10(457). PMC: 6592848. DOI: 10.1126/scitranslmed.aar8477. View

17.

Laviolette M, Gossage D, Gauvreau G, Leigh R, Olivenstein R, Katial R . Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013; 132(5):1086-1096.e5. PMC: 4172321. DOI: 10.1016/j.jaci.2013.05.020. View

18.

Bormioli S, Vultaggio A, Nencini F, Comin C, Bercich L, Bezzi M . Benralizumab: Resolution of Eosinophilic Pulmonary Vasculitis in a Patient With EGPA. J Investig Allergol Clin Immunol. 2021; 31(6):519-521. DOI: 10.18176/jiaci.0689. View